PMEF
KRTX

Point72 Middle East FZE’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Point72 Middle East FZE’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,370
Closed -$269K – 2346
2022
Q4 		$269K Buy
+1,370
New +$294K 0.01% 931

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Middle East FZE's KRTX Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2023, closing a stake of 1,370 shares — an estimated $269K sold.

Point72 Middle East FZE first reported a position in KRTX in Q4 2022 and held it in 1 quarter. The position peaked at $269K in Q4 2022. 246 funds tracked by Wall St. Rank hold KRTX as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,370 Karuna Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $269K.
  • Point72 Middle East FZE first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Karuna Therapeutics, Inc. Common Stock position peaked at $269K in Q4 2022.
  • 246 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.